Adverse events of immune checkpoint inhibitors for patients with digestive system cancers: A systematic review and meta-analysis.

ABSTRACT:

Objective

To study the incidence and distribution of adverse events in immune checkpoint inhibitors (ICI) for digestive system cancers and to provide a reference for the safe, rational, and effective use of immune detection site inhibitors.

Methods

We searched for articles published in English between January 1, 2010, and May 18, 2022. All clinical trials of ICI-based therapies for digestive system cancers were investigated, including only randomized controlled trials that reported data on the overall incidence of treatment-related adverse events (trAEs) or immune-related adverse reactions (irAEs) or tables.

Results

We searched 2048 records, of which 21 studies (7108 patients) were eligible for inclusion. The incidence of ICI trAEs of any grade was 82.7% (95% CI 73.9-

SUBMITTER: Kou L 

PROVIDER: S-EPMC9634077 | biostudies-literature | 2022

REPOSITORIES: biostudies-literature